DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and ZL-1310 is tolerated when given with another medicine called a checkpoint inhibitor. Another purpose is to check whether the study treatment can stop the cancer from growing and keep it stable. Obrixtamig and ZL-1310 are being developed to help the immune system fight cancer. In Part 1, participants get obrixtamig an

Trial Details

NCT ID
NCT07707895
Phase
PHASE1 / PHASE2
Sponsor
Boehringer Ingelheim
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Obrixtamig
  • ZL-1310
  • Atezolizumab
Locations (sample)
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Tampa, Florida, United States|27.94752,-82.45843
  • Lexington, Kentucky, United States|37.98869,-84.47772
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • St Leonards, New South Wales, Australia|-33.82344,151.19836

Key Eligibility Criteria

  • For Part 1
  • Diagnosed with locally advanced, metastatic or relapsed cancer of the following histologies:
  • Small cell lung carcinoma (SCLC)
  • Large cell neuroendocrine lung carcinoma (LCNEC-L)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →